巨子生物“造假门”升级，两大医美巨头隔空叫板

Core Viewpoint - The ongoing controversy surrounding Juzhi Biotechnology's alleged product fraud has escalated into a significant conflict within the medical aesthetics industry, involving major players like Huaxi Biotechnology and self-media influencer Gao Yu [1][3]. Group 1: Incident Development - The scandal began with allegations of Juzhi Biotechnology's collagen product being falsely represented, leading to a public dispute with Gao Yu, who claimed the product contained only 0.0177% of the required collagen, below the legal threshold of 0.1% [4][9]. - On May 30, the testing agency that supported Gao Yu retracted its report, which Juzhi interpreted as an apology, while still contesting the validity of Gao Yu's testing methods [2][3]. - The controversy has prompted other companies in the industry to begin testing their products, with over 100 samples submitted for testing by nine different companies [7]. Group 2: Industry Impact - The product in question, "Kefumei Human-Like Recombinant Collagen Essence," has been a core revenue driver for Juzhi, generating approximately 4.542 billion yuan in revenue in 2024, accounting for about 82% of the company's total revenue [9]. - Huaxi Biotechnology's involvement has intensified the situation, as they publicly supported Gao Yu and criticized the tactics used by Juzhi, suggesting a broader industry conflict [12][15]. - Following Huaxi's announcement, their stock rose by 6.94%, while Juzhi's stock fell by 4.69%, reflecting the market's reaction to the unfolding drama [16].